You Shuai

Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

The N6-methyladenosine writer METTL3 promotes breast cancer progression through YTHDF2-dependent posttranscriptional silencing of GSDMD.

The N6-methyladenosine writer METTL3 promotes breast cancer progression through YTHDF2-dependent posttranscriptional silencing of GSDMD.

Journal: Apoptosis : an international journal on programmed cell death

Published: October 24, 2024

Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization.

Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization.

Journal: Human vaccines & immunotherapeutics

Published: October 08, 2024

MNX1-AS1 suppresses chemosensitivity by activating the PI3K/AKT pathway in breast cancer.

MNX1-AS1 suppresses chemosensitivity by activating the PI3K/AKT pathway in breast cancer.

Journal: International journal of biological sciences

Published: October 01, 2024

Genetic associations of plasma proteins and breast cancer identify potential therapeutic drug candidates.

Genetic associations of plasma proteins and breast cancer identify potential therapeutic drug candidates.

Journal: Communications biology

Published: June 19, 2024

LINC01503 in cancer: from molecular mechanisms to therapeutic implications.

LINC01503 in cancer: from molecular mechanisms to therapeutic implications.

Journal: Clinical and experimental medicine

Published: May 07, 2024

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.

Journal: Thoracic cancer

Published: November 10, 2023

Liquid-based biomarkers in breast cancer: looking beyond the blood.

Liquid-based biomarkers in breast cancer: looking beyond the blood.

Journal: Journal of translational medicine

Published: May 23, 2023

Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis.

Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis.

Journal: Frontiers in oncology

Published: November 16, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026